Other research analysts also recently issued reports about the company. DZ Bank reissued a buy rating on shares of Gerresheimer in a research note on Thursday, July 12th. Berenberg Bank set a €78.00 ($90.70) price objective on Gerresheimer and gave the company a buy rating in a research note on Tuesday, July 10th. Credit Suisse Group set a €72.00 ($83.72) price objective on Gerresheimer and gave the company a buy rating in a research note on Monday, July 9th. Deutsche Bank set a €77.00 ($89.53) price objective on Gerresheimer and gave the company a buy rating in a research note on Tuesday, June 19th. Finally, equinet set a €69.00 ($80.23) price objective on Gerresheimer and gave the company a neutral rating in a research note on Thursday, July 12th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the company’s stock. Gerresheimer presently has a consensus rating of Hold and a consensus target price of €72.50 ($84.30).
Shares of GXI stock opened at €71.20 ($82.79) on Tuesday. Gerresheimer has a twelve month low of €59.97 ($69.73) and a twelve month high of €78.25 ($90.99).
Gerresheimer AG manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. It operates through two divisions, Plastics & Devices, and Primary Packaging Glass. The Plastics & Devices division offers drug delivery systems, including inhalers, pen systems, and injection systems; sterile and non-sterile prefillable syringe systems for the pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables and components for dialysis machines, and catheters and surgical devices.
See Also: Do You Need a Fiduciary?
Receive News & Ratings for Gerresheimer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gerresheimer and related companies with MarketBeat.com's FREE daily email newsletter.